scaav-cmv-gfp  (Vector Biolabs)

Journal: JACC: Basic to Translational Science

Article Title: IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease

doi: 10.1016/j.jacbts.2022.12.006

Figure Lengend Snippet: Establishment of the Optimal AAV Dosing and Delivery Strategy for the Critically Ischemic Limb (A) Graphic abstract of study design and adeno-associated virus (AAV) injection volumes and titers (viral genomes [vg]), created with Biorender.com . FAL = femoral artery ligation. (B) Representative images of tibialis anterior, extensor digitorum longus, soleus, flexor digitorum brevis, and gastrocnemius muscles injected with self-complimentary (sc) AAV9-–cytomegalovirus–green fluorescent protein (GFP) (n = 5-6/group) 35 days after FAL surgery. (C) Quantification of the GFP expression intensity (integral of area and intensity) across ischemic hindlimb muscles (n = 5-6/group). (D) Laser Doppler paw and gastrocnemius muscle perfusion recovery (n = 3-6/group). Error bars represent SD. C : 1-way ANOVA with Tukey’s post hoc test; D : repeated-measures ANOVA. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

Article Snippet: The scAAV–cytomegalovirus (CMV)–GFP plasmid was purchased from Cell Biolabs (cat. no. AAV410).

Techniques: Injection, Ligation, Expressing

Journal: JACC: Basic to Translational Science

Article Title: IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease

doi: 10.1016/j.jacbts.2022.12.006

Figure Lengend Snippet: AAV Injection Does Not Alter Myofiber Size or Histopathology in Critically Ischemic Muscle (A) Representative hematoxylin-eosin images of tibialis anterior and gastrocnemius muscles injected with scAAV9-CMV-GFP. (B) Quantification of mean myofiber area of hindlimb muscles (n = 3-6/group). The solid line represents the mean and dotted lines the SD of nonischemic muscle. (C) Histograms showing distribution of myofiber in hindlimb muscles. (D) Quantification of the ischemic lesion area (percentage of muscle injured). (E) Quantification of nonfiber area (percentage of total muscle area). Error bars represent SD. B, D, and E : 1-way ANOVA with Tukey’s post hoc test. Abbreviations as in Figure 1 .

Article Snippet: The scAAV–cytomegalovirus (CMV)–GFP plasmid was purchased from Cell Biolabs (cat. no. AAV410).

Techniques: Injection, Histopathology

Journal: bioRxiv

Article Title: IGF-1 therapy improves muscle size and function in experimental peripheral arterial disease

doi: 10.1101/2022.07.31.502209

Figure Lengend Snippet: (A) Graphical abstract of study design created using Biorender.com and AAV injection volumes. (B) Representative images of tibialis anterior, extensor digitorum longus, soleus, flexor digitorum brevis, and gastrocnemius muscles injected with scAAV9-CMV-GFP (n=5-6/group) 35 days post-FAL surgery. (C) Quantification of the GFP expression intensity (integral of area and intensity) across ischemic hindlimb muscles (n=5-6/group). (D) Laser Doppler paw and gastrocnemius muscle perfusion recovery (n=3-6/group). Error bars represent SD. Panels C and D were analyzed using Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons testing.

Article Snippet: The scAAV-CMV-GFP plasmid was purchased from Cell Biolabs (Cat. No. AAV410).

Techniques: Injection, Expressing

Journal: bioRxiv

Article Title: IGF-1 therapy improves muscle size and function in experimental peripheral arterial disease

doi: 10.1101/2022.07.31.502209

Figure Lengend Snippet: (A) Representative H&E images of tibialis anterior and gastrocnemius muscle injected with scAAV9-CMV-GFP. (B) Quantification of mean of myofiber area of hindlimb muscles (n=3-6/group). (C) Histograms showing distributions of myofiber in hindlimb muscles. (D) Quantification of the ischemic lesion area (percentage of muscle injured). (E) Quantification of non-fiber area (percentage of total muscle area). Error bars represent SD. Panels B, D, and E were analyzed using Brown-Forsythe and Welch ANOVA. The solid line represents the mean and dotted lines the SD of non-ischemic muscle.

Article Snippet: The scAAV-CMV-GFP plasmid was purchased from Cell Biolabs (Cat. No. AAV410).

Techniques: Injection